Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03853876 · ClinicalTrials.gov registry record
A Natural History Study of Aspartylglucosaminuria
A clinical trial, sponsored by Neurogene.
- Terminated
- Registry status
- 8
- Enrollment target
NCT03853876 is a clinical trial that was terminated before completion, run by Neurogene. The registered enrollment target is 8 participants.
The verdict
NCT03853876 was terminated before completion, sponsored by Neurogene.
- TERMINATED
- Registry status
- 8 participants
- Enrollment target
Study Summary
Aspartylglucosaminuria (AGU) is a rare neurodegenerative lysosomal storage disease (LSD) characterized by developmental delay, psychomotor regression, worsening intellectual disability, gait disturbance and, ultimately, premature death, and has no available treatments. The purpose of this study is to investigate the clinical characteristics and natural clinical progression of symptoms in individuals with AGU. This natural history study is important to better understand disease course to be able to determine clinically meaningful outcome measures for use in future clinical trials.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2019-04-18 |
| Est. Completion | 2022-03-17 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03853876
The ClinicalTrials.gov registry entry for NCT03853876 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neurogene, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03853876 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03853876 about?
NCT03853876 is a clinical study titled "A Natural History Study of Aspartylglucosaminuria". Aspartylglucosaminuria (AGU) is a rare neurodegenerative lysosomal storage disease (LSD) characterized by developmental delay, psychomotor regression, worsening intellectual disability, gait disturbance and, ultimately, premature death, and has no available treatments. The purpose of this study is ...
What is the current status of trial NCT03853876?
This trial is currently terminated. The enrollment target is 8 participants. The study started on 2019-04-18. Estimated completion is 2022-03-17.
Who is sponsoring clinical trial NCT03853876?
This trial is sponsored by Neurogene, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.